ReviewPharmacoEconomics1993
Epoetin: a pharmacoeconomic review of its use in chronic renal failure and its effects on quality of life.
Review in PharmacoEconomics, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 23 citations in OpenAlex.
- A decision analysis comparing three dosage regimens of subcutaneous epoetin in continuous ambulatory peritoneal dialysis.PharmacoEconomics · 1995Trial
- Male Sexual Dysfunction and Chronic Kidney Disease.Frontiers in medicine · 2017Review
- Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2006Article
- Review
- Epoetin alfa. A review of its clinical efficacy in the management of anaemia associated with renal failure and chronic disease and its use in surgical patients.Drugs & aging · 1995Review
- Development of the kidney disease quality of life (KDQOL) instrument.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 1994Article
- Low-dosage epoetin in maintenance haemodialysis: costs and quality-of-life improvement.PharmacoEconomics · 1994Review
- Cyclosporin: a pharmacoeconomic evaluation of its use in renal transplantation.PharmacoEconomics · 1993Review
- Determinants of hospital drug expenditures in Western Europe.PharmacoEconomics · 1993Article
- Drug utilisation review and pharmacoeconomics: interaction after parallel development?PharmacoEconomics · 1993Review
- Economic evaluation of pharmaceuticals: a European perspective.PharmacoEconomics · 1993Review
- Novel monoclonal antiendotoxin antibody therapy: efficacy at any price?PharmacoEconomics · 1993Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epoetin (recombinant human erythropoietin) is an effective treatment for the anaemia of patients with chronic renal failure. It is well tolerated, and the risk of adverse effects that are caused by too rapid a correction of anaemia, for example hypertension, can be reduced in most cases by lower starting dosage regimens. Epoetin improves the quality of life of anaemic patients with end-stage renal disease (ESRD), and significant improvements in most parameters of the Kidney Disease Questionnaire, the Sickness Impact Profile and the Nottingham Health Profile have been reported by patients. However, acquisition costs of epoetin are high, thereby adding a considerable cost to ESRD therapy despite a reduction in blood transfusion requirements. Notwithstanding, although cost-effectiveness studies have indicated that epoetin is associated with higher costs of therapy, cost-benefit analysis indicates that these costs can be reduced markedly with low-dose regimens and may be completely recovered if patients regain employment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.